siRNA Delivery to the Lung: What’s New?

Related Articles

siRNA Delivery to the Lung: What’s New?

Adv Drug Deliv Rev. 2014 Jun 4;

Authors: Merkel OM, Rubinstein I, Kissel T

RNA interference (RNAi) has been thought of as the general answer to many unmet medical needs. After the first success stories, it soon became obvious that short interfering RNA (siRNA) is not suitable for systemic administration due to its poor pharmacokinetics. Therefore local administration routes have been adopted for more successful in vivo RNAi. This paper reviews nucleic acid modifications, nanocarrier chemistry, animal models used in successful pulmonary siRNA delivery, as well as clinical translation approaches. We summarize what has been published recently and conclude with the potential problems that may still hamper the efficient clinical application of RNAi in the lung.

PMID: 24907426 [PubMed – as supplied by publisher]

View full post on pubmed: asthma